Verastem, Inc.

3 results found.

Malignant Pleural Mesothelioma Clinical Trial using defactinib (VS-6063); Placebo

Verastem, Inc. - Recruiting 18 years or older.
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma.
defactinib (VS-6063); Placebo

Non Small Cell Lung Cancer, or Lung Cancer Clinical Trial using defactinib (VS-6063)

Verastem, Inc. - Recruiting 18 years or older.
- Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer.
defactinib (VS-6063)

Non Hematologic Cancers, Metastatic Cancer, or Lymphoma Clinical Trial using VS-5584

Verastem, Inc. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma.
VS-5584